in a multicentre phase iii trial 105 previously untreated patients with high-grade non-hodgkin 's lymphomas stage ii-iv were randomized to receive either 4 cycles of choep ( cyclophosphamide 750 mg/m2 i.v . day 1 , doxorubicin 50 mg/m2 i.v . day 1 , vincristine 2 mg i.v . day 1 , etoposide 100 mg/m2 i.v . days 3-5 , prednisolone 100 mg p.o . days 1-5 ) ( treatment arm a ) , or 4 cycles of chemotherapy with hchop ( cyclophosphamide 1,200 mg/m2 i.v . day 1 , doxorubicin 40 mg/m2 i.v . days 1 + 2 , vincristine 2 mg i.v . day 1 , prednisolone 100 mg p.o . days 1-5 ) alternating with ivep ( ifosfamide 1,500 mg/m2 i.v . days 1-5 , vindesine 3 mg/m2 i.v . day 1 , etoposide 120 mg/m2 i.v . days 3-5 , prednisolone 100 mg p.o . days 1-5 ) in treatment arm b .
C0010583
cyclophosphamide
C0020823
ifosfamide